The approval of medicines called second-generation antipsychotics has allowed bipolar I and some conditions that come with it to be treated. A person who has bipolar I disorder can go through various ...
It is used to treat adults and adolescents aged 15 years and older who suffer from a disease characterised by symptoms such as hearing, seeing or sensing things which are not there, suspiciousness, ...
In addition to administration as a tablet, ABILIFY is available in a 1 mg/mL nonrefrigerated oral solution. The safety of doses of ABILIFY above 30 mg/day has not been evaluated in clinical trials.
PRINCETON, NJ and TOKYO, JAPAN, November 20, 2007 – Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) ...
TOKYO, JAPAN and PRINCETON, NJ, Nov. 6, 2007 -- Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the U.S. Food and Drug Administration (FDA) approved ...
Longer-acting formulas have made the treatment of schizophrenia more convenient and reliable for patients. Now, stepping to the plate with another long-acting treatment are Otsuka and Lundbeck. On ...
The FINANCIAL — Teva Pharmaceutical Industries Ltd., on April 28 announced the launch of the generic equivalent to Abilify (aripiprazole) Tablets, 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg, in the ...
TOKYO & REDWOOD CITY, Calif.--(BUSINESS WIRE)--Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Proteus Digital Health (Proteus) today announced that the United States Food and Drug Administration (FDA) ...
Credit: Thinkstock. Abilify Asimtufii is intended for dosing every 2 months via intramuscular injection in the gluteal muscle. The Food and Drug Administration (FDA) has approved Abilify Asimtufii ® ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback